Ernexa Therapeutics Inc. (ERNA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ernexa Therapeutics Inc. on May 1, 2026. The report details a corporate action involving the Company's capital structure, specifically a reverse stock split of its common stock.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event rather than financial performance.
Material Changes
- Reverse Stock Split: On May 1, 2026, the Company filed a Certificate of Amendment to effect a 1-for-25 reverse stock split of its common stock.
- Trading Adjustment: Effective at market open on May 4, 2026, the common stock began trading on a split-adjusted basis on The Nasdaq Stock Market LLC.
- Security Identification: The new CUSIP number for the common stock following the split is 114082407.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves solely to disclose the amendment to the Restated Certificate of Incorporation.
Investor Verification Checklist
- Verify the new CUSIP number (114082407) for trading and settlement purposes.
- Confirm the 1-for-25 split ratio has been applied to existing holdings.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for any additional terms not summarized in this report.
- Monitor the stock price and volume on Nasdaq starting May 4, 2026, for post-split trading activity.